TY - JOUR
T1 - Zika virus
T2 - advancing a priority research agenda for preparedness and response
AU - Zika Expert Workgroup
AU - Lackritz, Eve M.
AU - Ng, Lee Ching
AU - Marques, Ernesto T.A.
AU - Rabe, Ingrid B.
AU - Bourne, Nigel
AU - Staples, J. Erin
AU - Méndez-Rico, Jairo A.
AU - Harris, Eva
AU - Brault, Aaron C.
AU - Ko, Albert I.
AU - Beasley, David W.C.
AU - Leighton, Tabitha
AU - Wilder-Smith, Annelies
AU - Ostrowsky, Julia T.
AU - Mehr, Angela J.
AU - Ulrich, Angela K.
AU - Velayudhan, Raman
AU - Golding, Josephine P.
AU - Fay, Petra C.
AU - Cehovin, Ana
AU - Moua, Nicolina M.
AU - Moore, Kristine A.
AU - Osterholm, Michael T.
AU - Barrett, Alan
N1 - Publisher Copyright:
© 2025 Elsevier Ltd
PY - 2025
Y1 - 2025
N2 - The 2015–16 Zika virus epidemic emerged in the Americas and rapidly spread throughout the region and beyond, showing the epidemic potential of this mosquito-borne Orthoflavivirus and its capacity to cause severe congenital malformations and neurological sequelae. WHO declared the Zika virus epidemic a public health emergency of international concern in 2016. Despite this declaration, there are no licensed Zika virus vaccines, therapeutics, or diagnostic tests appropriate for routine antenatal screening. To address this absence of essential tools to detect and mitigate the threat of future Zika virus outbreaks, a group of global experts developed a priority agenda for Zika virus research and development. This Series paper summarises crucial challenges and knowledge gaps and outlines a comprehensive strategy to advance research, surveillance, global capacity, policy, and investment for Zika virus preparedness and response.
AB - The 2015–16 Zika virus epidemic emerged in the Americas and rapidly spread throughout the region and beyond, showing the epidemic potential of this mosquito-borne Orthoflavivirus and its capacity to cause severe congenital malformations and neurological sequelae. WHO declared the Zika virus epidemic a public health emergency of international concern in 2016. Despite this declaration, there are no licensed Zika virus vaccines, therapeutics, or diagnostic tests appropriate for routine antenatal screening. To address this absence of essential tools to detect and mitigate the threat of future Zika virus outbreaks, a group of global experts developed a priority agenda for Zika virus research and development. This Series paper summarises crucial challenges and knowledge gaps and outlines a comprehensive strategy to advance research, surveillance, global capacity, policy, and investment for Zika virus preparedness and response.
UR - http://www.scopus.com/inward/record.url?scp=105000800229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105000800229&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(24)00794-1
DO - 10.1016/S1473-3099(24)00794-1
M3 - Review article
C2 - 40024263
AN - SCOPUS:105000800229
SN - 1473-3099
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
ER -